ORIGINAL ARTICLESHumanised monoclonal antibody therapy for rheumatoid arthritis
References (23)
- et al.
A simple method for measuring patient anti-globulin responses against isotypic or idiotypic determinants
J Immunol Methods
(1990) - et al.
Removal of T cells from bone marrow for transplantation: a monoclonal anti-lymphocyte antibody that fixes human complement
Blood
(1983) - et al.
Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis
Lancet
(1991) - et al.
Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody
Lancet
(1991) Manipulation of T-cell responses with monoclonal antibodies
Annu Rev Immunol
(1989)- et al.
Immunotherapy of rheumatoid arthritis
Ann Rheumatol
(1992) The antiglobulin response to therapeutic antibodies
Semin Immunol
(1990)- et al.
Reshaping human antibodies for therapy
Nature
(1988) - et al.
Humanisation of monoclonal antibodies for therapy
Semin Immunol
(1990) - et al.
The CAMPATH-1 antigen (CDw52)
Tissue Antigens
(1990)
Genes associated with rheumatoid arthritis and mild inflammatory arthritis. II. Association of HLA with complement C3 and immunoglobulin Gm allotypes
Ann Rheum Dis
Cited by (306)
Immune monitoring of patients treated with anti-CD20 therapeutic monoclonals for autoimmune disorders
2023, Resistance to Anti-CD20 Antibodies and approaches for their Reversal: Volume 2Modulating T-cell activation with antisense oligonucleotides targeting lymphocyte cytosolic protein 2
2022, Journal of AutoimmunityAlemtuzumab in renal transplantation. Reviews of literature and usage in the United Kingdom
2022, Transplantation ReviewsCitation Excerpt :Over the subsequent years, Campath 1H was trialed in bone marrow transplants worldwide [24]. In 1988, Campath was evaluated for the treatment of patients with non-Hodgkin's lymphoma and vasculitis [28,29], and in 1991, studies were carried out in patients with rheumatoid arthritis and multiple sclerosis [30,31]. Further studies were also carried out in patients with chronic lymphocytic leukaemia (CLL) [32].
Tolerance-inducing medicines in autoimmunity: rheumatology and beyond
2020, The Lancet RheumatologyCitation Excerpt :Following renal transplantation, the addition of a rodent IgM CD52 mAb (Campath-1M) to standard immunosuppression reduced acute cellular rejection but increased serious infection risk.37 Studies of alemtuzumab (humanised Campath-1H) in rheumatoid arthritis suggested therapeutic benefit for some participants, often lasting for 6 months or longer after a brief course of therapy.38,39 These trials were curtailed largely because of chronic therapy-induced lymphopenia.
CD4 <sup>+</sup> CD52 <sup>lo</sup> T-cell expression contributes to the development of systemic lupus erythematosus
2018, Clinical ImmunologyCitation Excerpt :Soluble CD52 binds to siglec-10 on activated T cells, including CD4+ CD52lo T cells, which leads to the inhibition of these cells by impairing the phosphorylation of the T-cell receptor-associated kinases Lck and Zap70 [4]. An anti-CD52 antibody (alemtuzumab) has been used to treat multiple diseases: RA [13–15], non-Hodgkin's lymphoma [16,17], T-cell lymphoma [18,19], and relapsing-remitting multiple sclerosis [20,21]. The efficacy of alemtuzumab is brought about by anti-CD52 antibody-mediated lymphocytic depletion as immune ablation.
Immunotoxicology of Biopharmaceutics
2018, Comprehensive Toxicology: Third Edition